Asset Details
Do you wish to reserve the book?
The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
Do you wish to request the book?
The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines
2010
Overview
We recently reported the development of a successful post-exposure combination antiviral and “prime-boost” vaccination strategy using the duck hepatitis B virus (DHBV) model of human hepatitis B virus infection. The current study aimed to simplify the vaccination strategy and to test the post-exposure efficacy of combination therapy with the Bristol-Myers Squibb antiviral drug, entecavir (ETV) and either a single dose of DHBV DNA vaccines on day 0 post-infection (p.i.) or a single dose of recombinant fowlpoxvirus (rFPV–DHBV) vaccines on day 7 p.i. Whilst untreated control ducks infected with an equal dose of DHBV all developed persistent and wide spread DHBV infection of the liver, ducks treated with ETV combined with either the DHBV DNA vaccines on day 0 p.i. or the rFPV–DHBV vaccines on day 7 p.i. had no detectable DHBV-infected hepatocytes by day 14 p.i. and were protected from the development of persistent DHBV infection.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
/ Animals
/ Biological and medical sciences
/ DNA
/ DNA, Viral - isolation & purification
/ Duck hepatitis B virus (DHBV)
/ Fundamental and applied biological sciences. Psychology
/ Hepadnaviridae Infections - immunology
/ Hepadnaviridae Infections - prevention & control
/ Hepatitis Antibodies - blood
/ Hepatitis Antibodies - immunology
/ Hepatitis B Virus, Duck - immunology
/ Hepatitis, Viral, Animal - immunology
/ Hepatitis, Viral, Animal - prevention & control
/ Liver
/ Recombinant fowlpoxvirus (rFPV)
/ Studies
/ Vaccines
/ Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
/ Vaccines, Synthetic - immunology
/ Viral Envelope Proteins - immunology
/ Viral Hepatitis Vaccines - immunology
/ Virology
